News

Frontiers in molecular genetic diagnostics of pulmonary arterial hypertension (PAH)

Published on September 2, 2015

Genetic basis of pulmonary arterial hypertension (PAH) is well recognised but still rarely utilized in diagnostics setting. Diagnostic yield of comprehensive multi-gene panels in PAH is relatively unknown as current knowledge is gathered from studies evaluating only one gene at a time in a heterogenous patient populations.  Finnish PAH…

Read more

Investigating the genetic landscape of DCM in the Finnish population

Published on August 27, 2015

To explore the underlying genetic defects of dilated cardiomyopathy (DCM) we applied OS-Seq technology as a novel comprehensive diagnostic tool. Despite our increasing understanding of the genetics of DCM the genetic basis of the disease is still poorly understood. We were able to identify pathogenic variants in 47.6% of the…

Read more

Subscribe to our newsletter

Come meet us this spring at HRS, AEPC and ESHG

Published on April 13, 2015

We are continuously participating in events around the world. Come meet us at the following conferences during spring and summer 2015. More details about our participation, booth number etc. are also found on our Facebook page.    HRS – Heart Rhythm 2015 36th Annual Scientific…

Read more

Exceptional findings with OS-Seq in an arrhythmia patient

Published on April 9, 2015

Sequencing of channelopathy genes with the BpG Arrhythmia Panel revealed a de novo mutation in the CACNA1C gene in an adolescent with ventricular fibrillation but normal development, consequently not only expanding the phenotype of Timothy Syndrome Type 2 but also demonstrating the power of large gene panels. The standard has been to select specific gene tests for patients with established…

Read more

Meet Sampo, our new NextSeq 500 Desktop Sequencer

Published on March 27, 2015

We have a tradition of naming our sequencing machines after famous robots. Our latest system is called Sampo. In the Finnish national epoch compiled by Elias Lönnrot, Kalevala, Sampo is described as a refiner engine that brought prosperity to its owner. Pretty witty, huh? Currently, we are using Illumina’s MiSeqs…

Read more

One of the 20 most promising start-ups in Finland 2015

Published on March 25, 2015

Finnish business magazine Talouselämä has released its take on the 20 most promising start-ups in Finland. Blueprint Genetics is one of the companies! Read more… (Order Talouselämä or try ’Summa’ one month for free to read the full story.)…

Read more

Big news for Blueprint Genetics at the 2015 Annual Clinical Genetics Meeting

Published on March 24, 2015

The 2015 Annual Clinical Genetics Meeting (ACMG) marks an important milestone for us at Blueprint Genetics, one of the leading laboratories in cardiovascular genetics. At this meeting we’re excited to announce our new and improved service model, plus our upcoming sales launch in the US. We’re opening new facilities…

Read more

Blueprint Genetics – Ready for 2015!

Published on December 18, 2014

Blueprint Genetics thanks all hospitals and clinics, which have collaborated with us and utilized our diagnostic services during year 2014 and wishes all of you a Happy New Year 2015! During 2014 our customer base has exceeded over 90 clinics and hospitals in 31 countries. From these hospitals we have…

Read more

Blueprint Genetics is launching new products neurological diseases

Published on November 3, 2014

Blueprint Genetics launches new genetic diagnostic tests for Becker and Duchenne muscular dystrophies and an updated panel for Emery-Dreifuss muscular dystrophy with the addition of titin (TTN) gene. In line with our other diagnostic panels, we target the sequencing to all protein coding exons, exon-intron boundaries and other regions with…

Read more

Blueprint Genetics Announces $3.9 Million in Funding, Leading to US Expansion

Published on August 29, 2014

Helsinki, Finland – August 29, 2014 – Blueprint Genetics is glad to announce that Inventure and Avohoidon Tutkimussäätiö, a Finnish foundation, have joined the existing investors of the company. Previously, the company has been financed by Finnish business angels and Tekes, the Finnish Funding Agency for Innovation. The funding for Blueprint Genetics now totals…

Read more

Blueprint Genetics Announces $3.9 Million in Funding, Leading to US Expansion

Published on August 29, 2014

Blueprint Genetics is glad to announce that Inventure and Avohoidon Tutkimussäätiö, a Finnish foundation, have joined the existing investors of the company. Previously, the company has been financed by Finnish business angels and Tekes, the Finnish Funding Agency for Innovation. The funding for Blueprint Genetics now totals $3.9 million, allowing the company to accelerate…

Read more

Blueprint Genetics’ NGS panels achieve leading analytic validity

Published on August 29, 2014

Blueprint Genetics (BpG) is proud to publish extensive validations for NGS panels in detection of single nucleotide polymorphisms (SNPs) and small insertions & deletions (indels). It is widely recognized that sequencing quality has significant impact on diagnostic yield when utilizing NGS technologies. BpG´s mission is to provide the highest possible…

Read more

Blueprint Genetics (BpG) launches a genetic test for periodic fever syndromes and adds two genes into the Hyperlipidemia Panel

Published on August 6, 2014

BpG Periodic Fever Syndrome Panel – New Panel Including 9 Genes Blueprint Genetics continues launching comprehensive next-generation sequencing (NGS) tests by releasing a best in class diagnostic panel for periodic fever syndromes (PFS). BpG Periodic Fever Syndrome Panel is the first effective genetic diagnostics tool for familial Mediterranean fever…

Read more

Updates on BpG Cardiovascular Panels

Published on May 6, 2014

Blueprint Genetics (BpG) is happy to launch new updated panels for cardiovascular diseases. Our team at BpG is constantly evaluating the latest findings in genetics and updating our mutation and clinical information databases and sequencing panels. Our mission is to provide our customers the most current and up-to-date diagnostics that…

Read more

Blueprint Genetics Boosts the Cost-Effectiveness of Family Member Testing

Published on April 24, 2014

Following the successful launch of our index diagnostic panels the number of family members tested at our laboratory has increased significantly during past months. The risk stratification of family members is one of the major reasons for genetic testing and we want to lower the barrier of testing further and…

Read more

Blueprint Genetics launches new tests for neurological diseases

Published on March 10, 2014

Blueprint Genetics launches new genetic diagnostic tests for Becker and Duchenne muscular dystrophies and an updated panel for Emery-Dreifuss muscular dystrophy with the addition of titin (TTN) gene. In line with our other diagnostic panels, we target the sequencing to all protein coding exons, exon-intron boundaries and other regions with…

Read more

Blueprint Genetics is launching new products for hyperlipidemia and nephrotic syndrome

Published on February 14, 2014

In 2013 Blueprint Genetics launched 14 comprehensive diagnostic NGS panels for hereditary cardiovascular diseases and certain neurological disorders. As previously, our service with inclusive clinical statements and interpretations has been continuing to receive excellent feedback from our customers. The number of ordering hospitals has been increasing and to date physicians…

Read more

Geneticist position – Blueprint Genetics

Published on January 15, 2014

Blueprint Genetics (BpG) is looking for a highly motivated and exceptional geneticist or clinical geneticist for a full-time position, starting 1st of April 2014 or as negotiated. BpG is a Next Generation Sequencing start-up company based in Helsinki, Finland. We are a team of eleven professionals running a clinical grade…

Read more

Blueprint Genetics accepted into the Tekes NIY program

Published on December 12, 2013

We are happy to announce that Blueprint Genetics has been accepted into the NIY program of Tekes (The Finnish National Technology Agency). The program has two phases that enables us to withdraw up to one million euros in subvention when challenging objectives are met. The idea of…

Read more